<DOC>
	<DOCNO>NCT00030784</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine liposomal doxorubicin ifosfamide treat patient advanced metastatic soft tissue sarcoma .</brief_summary>
	<brief_title>Liposomal Doxorubicin Plus Ifosfamide Treating Patients With Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ifosfamide combination doxorubicin HCl liposome patient previously untreated advanced metastatic soft tissue sarcoma . - Determine objective response patient treat regimen . - Determine dose-limiting toxicity patient treated regimen . OUTLINE : This multicenter , dose-escalation study ifosfamide . Patients receive doxorubicin HCl liposome IV 1 hour day 1 ifosfamide IV 4 hour day 1-3 OR day 1-4 ( patient enrol dose level 6 ) . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ifosfamide maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 8 week disease progression every 12 week thereafter . PROJECTED ACCRUAL : A total 3-24 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma Advanced and/or metastatic disease Must follow type : Malignant fibrous histiocytoma Liposarcoma ( exclude lipomas welldifferentiated liposarcoma ) Rhabdomyosarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma Neurogenic sarcoma Sarcoma otherwise specify Paraffin block slide must available Measurable disease Osseous lesions pleural effusion consider measurable disease Evidence progressive disease within past 6 week The following condition exclude : Gastrointestinal stromal tumor Malignant mesothelioma Chondrosarcoma Neuroblastoma Osteosarcoma Ewing 's sarcoma Embryonal rhabdomyosarcoma No symptomatic know CNS metastases PATIENT CHARACTERISTICS : Age : 18 70 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.75 mg/dL Albumin least 2.5 g/dL Renal : Creatinine great 1.4 mg/dL Creatinine clearance least 65 mL/min Cardiovascular : Ejection fraction least 50 % echocardiogram isotopic method No history cardiovascular disease Other : No prior concurrent primary malignancy except adequately treat carcinoma situ cervix basal cell carcinoma No severe medical illness No psychosis No psychological , familial , sociological , geographical condition would preclude study participation Not pregnant Fertile patient must use effective contraception ( barrier method men ) 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy advance disease No concurrent systemic chemotherapy malignancy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy sole indicator lesion Concurrent radiotherapy allow except sole indicator lesion Surgery : Not specify Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>